Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy

Nadeem Ali Dhirani1 Wayne State University School of Medicine, Detroit, MI, USA

Yelin Yang2 Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON

Sohel Somani2 Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON;3 William Osler Health System, Brampton, ON;4 Uptown Eye Specialists, Brampton, ON, CanadaCorrespondence[email protected]

Pages 2145-2149 | Published online: 06 Dec 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

PiccolinoFCBorgiaLZinicolaEZingirianMIndocyanine green angiographic findings in central serous chorioretinopathyEye (Lond)19959Pt 33243327556741
PubMed Web of Science ®Google Scholar
NicholsonBNobleJForooghianFMeyerleCCentral serous chorioretinopathy: update on pathophysiology and treatmentSurv Ophthalmol201358210312623410821
PubMed Web of Science ®Google Scholar
LiewGQuinGGilliesMFraser-BellSCentral serous chorioretinopathy: a review of epidemiology and pathophysiologyClin Exp Ophthalmol201341220121422788735
PubMed Web of Science ®Google Scholar
WangMMunchICHaslerPWPrunteCLarsenMCentral serous chorioretinopathyActa Ophthalmol200886212614517662099
PubMed Web of Science ®Google Scholar
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials – TAP report. treatment of age-related macular degeneration with photodynamic therapy (TAP) study groupArch Ophthalmol1999117101329134510532441
PubMed Web of Science ®Google Scholar
ChanWMLaiTYLaiRYLiuDTLamDSHalf-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: One-year results of a randomized controlled trialOphthalmology2008115101756176518538401
PubMed Web of Science ®Google Scholar
Cardillo PiccolinoFEandiCMVentreLRigault de la LongraisRCGrignoloFMPhotodynamic therapy for chronic central serous chorioretinopathyRetina200323675276314707823
PubMed Web of Science ®Google Scholar
ChanWMLamDSLaiTYTamBSLiuDTChanCKChoroidal vascular remodelling in central serous chorioretinopathy after indo-cyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease levelBr J Ophthalmol200387121453145814660450
PubMed Web of Science ®Google Scholar
ReibaldiMCardasciaNLongoAStandard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: A nonrandomized clinical trialAm J Ophthalmol20101492307315.e219896635
PubMed Web of Science ®Google Scholar
NicoloMEandiCMAlovisiCHalf-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathyAm J Ophthalmol201415751033103724487046
PubMed Web of Science ®Google Scholar
LaiTYWongRLChanWMLong-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (an american ophthalmological society thesis)Trans Am Ophthalmol Soc2015113T826755855
PubMedGoogle Scholar
YannuzziLASlakterJSGrossNEIndocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: A pilot studyRetina200323328829812824827
PubMed Web of Science ®Google Scholar
BreukinkMBMohrJKOssewaarde-van NorelAHalf-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocolActa Ophthalmol201694218719726670630
PubMed Web of Science ®Google Scholar
UetaniRItoYOiwaKIshikawaKTerasakiHHalf-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathyEye (Lond)201226564064922573069
PubMed Web of Science ®Google Scholar
ButlerALFungATMerkurABAlbianiDAForooghianFVery minimal fluence photodynamic therapy for chronic central serous chorioretinopathyCan J Ophthalmol2012471424422333850
PubMed Web of Science ®Google Scholar
KimYKRyooNKWooSJParkKHComparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathyGraefes Arch Clin Exp Ophthalmol2015253122063207325616728
PubMed Web of Science ®Google Scholar
ChengCKChangCKPengCHComparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathyRetina201737232533327429374
PubMed Web of Science ®Google Scholar
AlkinZPerenteIOzkayaAComparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathyClin Ophthalmol2014868569024741287
PubMedGoogle Scholar
AlkinZYilmazIOzkayaAYaziciATSteroid-induced central serous chorioretinopathy in a patient with non-arteritic anterior ischemic optic neuropathySaudi J Ophthalmol201529323223426155086
PubMedGoogle Scholar
KimYKRyooNKWooSJParkKHChoroidal thickness changes after photodynamic therapy and recurrence of chronic central serous chorioretinopathyAm J Ophthalmol201516017284.e125887629
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date